An aide memoire for model-based drug development--a new key for the interpretation of the erythromycin breath test--therapeutic index as a biomarker for smart drug development

Affiliations

Comment

Bruno Boutouyrie-Dumont. Biomark Med. 2013 Feb.

. 2013 Feb;7(1):89-91.

doi: 10.2217/bmm.12.101.

¹ Clinical Pharmacology Department, Shire AG, Business Park Terre-Bonne, Route de Crassier 15, 1262 Eysins, Switzerland. bbdumont@shire.com

No abstract available

Comment on

Quantitative analysis to guide orphan drug development.
Lesko LJ. Lesko LJ. Clin Pharmacol Ther. 2012 Aug;92(2):258-61. doi: 10.1038/clpt.2012.80. Epub 2012 Jun 27. Clin Pharmacol Ther. 2012. PMID: 22739138
The determination and interpretation of the therapeutic index in drug development.
Muller PY, Milton MN. Muller PY, et al. Nat Rev Drug Discov. 2012 Oct;11(10):751-61. doi: 10.1038/nrd3801. Epub 2012 Aug 31. Nat Rev Drug Discov. 2012. PMID: 22935759 Review.
OATP1B1 polymorphism as a determinant of erythromycin disposition.
Lancaster CS, Bruun GH, Peer CJ, Mikkelsen TS, Corydon TJ, Gibson AA, Hu S, Orwick SJ, Mathijssen RH, Figg WD, Baker SD, Sparreboom A. Lancaster CS, et al. Clin Pharmacol Ther. 2012 Nov;92(5):642-50. doi: 10.1038/clpt.2012.106. Epub 2012 Sep 19. Clin Pharmacol Ther. 2012. PMID: 22990751 Free PMC article. Clinical Trial.